Novo Shares Fall After CagriSema Results in Diabetes Patients
Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema showed 15.7% weight ...
Is the obesity drug market still a duopoly?
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
BioSpace7h
GLP-1 Side Effects Only One Factor Driving Patient Discontinuation Rates
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
Weight-loss drug battle: Who are the latest players involved
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
7 Best Weight Loss Drug Stocks to Buy in 2025
Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...
Medical Marketing & Media2d
Novo, Lilly and Novartis lead pharma’s stellar ad performance at Oscars
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
Makers of Wegovy and Zepbound cut prices for those without insurance
The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance. Novo Nordisk, the Danish company behind Wegovy, ...
US judge denies injunction, restricting copies of Lilly weight-loss drug
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...
HealthDay2d
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance
The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more af ...